Details
Stereochemistry | UNKNOWN |
Molecular Formula | C14H20N4O |
Molecular Weight | 260.3348 |
Optical Activity | ( - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(C1CONC(=N1)C2=CC=CN=C2)N3CCCCC3
InChI
InChIKey=QWVRTSZDKPRPDF-UHFFFAOYSA-N
InChI=1S/C14H20N4O/c1-2-7-18(8-3-1)10-13-11-19-17-14(16-13)12-5-4-6-15-9-12/h4-6,9,13H,1-3,7-8,10-11H2,(H,16,17)
IROXANADINE, a pyridine derivative, is under development for the treatment of atherosclerosis and the complications of atherosclerosis such as ischaemic heart disease, peripheral arterial disease, and restenosis. It induces phosphorylation of p38 stress-activated protein kinase, which plays an important role in endothelial cells (EC) homeostasis. EC function plays a central role in vascular diseases.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. | 2002 Jun |
|
Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. | 2004 Dec |
|
Reverse regulation of endothelial cells and myointimal hyperplasia on cell proliferation by a heatshock protein-coinducer after hypoxia. | 2008 Mar |
|
Restenosis and therapy. | 2012 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15583868
Iroxanadine (BRX-235) may improve survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. Addition of BRX-235 (0.1-1 microM) to culture medium prior to hypoxia or at start of reoxygenation significantly reduced the caspase-dependent apoptosis. The cytoprotection conferred by the pre-hypoxic drug administration was sensitive to quercetin and seems to be based on enhanced heat shock protein accumulation in stressed ECs.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2079
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40950313
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107433
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
DB05444
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
C469852
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
6K69EJ1DL1
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
C83837
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
300000036931
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
276690-58-5
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
6421776
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY | |||
|
8257
Created by
admin on Fri Dec 15 17:26:55 GMT 2023 , Edited by admin on Fri Dec 15 17:26:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)